NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
204 trialsNCT05696626 2026-04-21
ELAINEIII
LeonaBio
Phase 3 Recruiting
NCT07100106 2026-04-21
MoonROSE
Genentech, Inc.
Phase 1/2 Recruiting
NCT04750928 2026-04-20
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04862663 2026-04-20
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT05307705 2026-04-20
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06413706 2026-04-20
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT06654037 2026-04-14
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04633239 2026-04-13
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT05372640 2026-04-13
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05440786 2026-04-13
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT06498648 2026-04-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06835972 2026-04-09
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06188520 2026-04-08
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT02523014 2026-04-07
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07112053 2026-04-06
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT06365788 2026-04-01
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT07492641 2026-03-25
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
BeOne Medicines
Phase 3 Not yet recruiting
NCT05413304 2026-03-24
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT07487129 2026-03-23
Clinical and P
Beni-Suef University
Phase 4 Completed
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05940493 2026-03-13
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2 Recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05524584 2026-03-11
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
Phase 2 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04393285 2026-03-09
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT04391595 2026-03-06
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT03531645 2026-03-05
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting